Republicans in Congress have shown more willingness to limit drugmakers' ability to thwart competition.

New York's Drug Utilization Review Board says the state's Medicaid program should pay no more for Janssen Pharmaceuticals' Remicade than it does for biosimilar versions.

A False Claims Act case in California alleges that Gilead Sciences used its Frontlines of Communities in the United States patient screening program to illegally pay physician salaries through grants, fund patient travel to HIV and hepatitis screenings, and pay for upgrades to health care providers' software, staff to write prescriptions, upgrades to laboratory equipment and dissemination of product efficacy information.

Drugmakers have set their prices so high that they are harming consumers, patients and taxpayers, and they have tried to shift the blame to everyone else in the supply chain, writes America's Health Insurance Plans President and CEO Matt Eyles. "Let's stop the nonsensical blame-shifting. Let's work together to hold Big Pharma accountable," Eyles writes.